General Requirements
Covered for all indications when ALL of the following requirements are met:
ALL of the following
Therapy is ordered by or provided in consultation with an appropriate specialist: rheumatologist, immunologist, dermatologist, gastroenterologist, or colorectal surgeon.
Initial approval is for 6 months.
Continuation approval may be granted for up to 12 months when documentation demonstrates improved member status.
Initial Therapy — Ankylosing Spondylitis
Covered for active moderate to severe ankylosing spondylitis when ALL of the following are met:
ALL of the following
Chart notes document failure of at least one trial of an NSAID at the maximum tolerated dose, unless the member has a contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
Chart notes document significant clinical symptoms, such as fatigue, spinal pain, arthralgia, inflammation of joints and tendons, and morning stiffness.
For patients with symptomatic peripheral arthritis, chart notes document an insufficient response to at least one local corticosteroid injection.
Initial Therapy — Crohn's Disease
Covered for active moderate to severe Crohn's disease confirmed by endoscopy, or by capsule endoscopy when appropriate, when the applicable requirements below are met:
ALL of the following
Active moderate to severe Crohn's disease is confirmed by endoscopy, or by capsule endoscopy when appropriate.
ONE of the following
The member is younger than 18 years; pediatric Crohn's disease requests will be reviewed on a case-by-case basis.
Documentation demonstrates failure or inadequate response to a 12-week trial of adalimumab.
Documentation provides a rationale explaining why the member or caregiver is unable to self-administer adalimumab.
Initial Therapy — Psoriatic Arthritis
Covered for moderate to severe active psoriatic arthritis when ALL of the following applicable requirements are met:
ALL of the following
The member has moderate to severe psoriatic arthritis, indicated by at least 3 tender joints and at least 3 swollen joints on 2 separate occasions at least 1 month apart.
Chart notes document use of at least one NSAID at the maximum tolerated dose, unless the member has a contraindication to NSAID therapy, such as cardiovascular disease, peptic ulcer disease, or renal disease.
ONE of the following
Chart notes document failure to respond to an adequate trial of at least 3 months, including 2 months at the standard target dose, of at least one DMARD: leflunomide, sulfasalazine, or methotrexate.
The member has pure axial manifestations; a trial of a nonbiologic DMARD is not required.
Initial Therapy — Rheumatoid Arthritis
Covered for active moderate to severe adult rheumatoid arthritis when ALL of the following applicable requirements are met:
ALL of the following
The member has active moderate to severe adult rheumatoid arthritis, defined by persistent or recurrent symptoms with documented synovitis and morning stiffness of significant duration that inhibits activities of daily living.
ONE of the following DMARD-history pathways
ALL of the following
Chart notes document failure to respond to one or more nonbiologic DMARDs, including a 3-month trial of methotrexate at the maximally tolerated dose.
Failure is demonstrated by the provider's assessment documenting no improvement in joint counts and/or physical symptoms and inflammatory markers while on therapy.
Initial Therapy — Ulcerative Colitis
Covered for active moderate to severe ulcerative colitis when ALL of the following applicable requirements are met:
ALL of the following
Chart notes document an inadequate response to or intolerance of conventional therapy, including anti-inflammatory aminosalicylates such as mesalamine (5-ASA) or sulfasalazine, 6-mercaptopurine, and azathioprine.
ONE of the following additional conditions
If conventional therapy is not appropriate, documentation provides rationale for the medical necessity of infliximab, such as a contraindication or disease severity; the request will be reviewed case-by-case in accordance with current American College of Gastroenterology guidelines.
The request is for pediatric ulcerative colitis and will be reviewed case-by-case in accordance with current American College of Gastroenterology guidelines.
Refractory Granulomatosis With Polyangiitis
Covered case-by-case when the following criterion is met:
ALL of the following
The request is for refractory granulomatosis with polyangiitis (Wegener's granulomatosis), and infliximab is used in combination with corticosteroids.
Immune Checkpoint Inhibitor-Related Diarrhea or Colitis
Covered only for the limited acute course when ALL of the following are met:
ALL of the following
The member has been receiving an immune checkpoint inhibitor, such as nivolumab, pembrolizumab, atezolizumab, avelumab, durvalumab, or cemiplimab.
The member has moderate (grade 2) to severe (grade 3–4) diarrhea or colitis related to immunotherapy.
Coverage is limited to infliximab 5 mg/kg, up to a maximum of 2 doses within 1 month.
Infliximab is not considered medically necessary when the indication, age, dose, frequency of dosing, or duration of therapy is outside FDA-approved package labeling.
Continuation of infliximab for immune checkpoint inhibitor-related diarrhea or colitis is not a covered benefit.
Infliximab is not considered medically necessary for members with a known hypersensitivity to murine proteins, heart failure (NYHA class III or IV) when dosed above 5 mg/kg, or use in combination with TNF blockers, other biologics, or an interleukin-1 inhibitor.